| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C19-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D489-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D489-08 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D489-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- |
| filingDate |
2004-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2007-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2007526217-A |
| titleOfInvention |
Polymorphic form of naltrexone |
| abstract |
The present invention relates to the discovery of new amorphous and polymorphic forms of naltrexone, including solvates, hydrates, anhydrides and other crystalline forms and combinations thereof. These novel forms of naltrexone provide advantages in pharmaceutical formulations containing it (such as sustained release or long acting formulations). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020067275-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015522534-A |
| priorityDate |
2003-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |